Landscape Capital Management, L.L.C. Chemo Centryx, Inc. Transaction History

Landscape Capital Management, L.L.C.

$887 Million
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2019 May 15, 2019	SELL	$10.01 - $13.89 $102,952 - $142,858	-10,285 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$10.49 - $13.72 $69,181 - $90,483	-6,595 Reduced 39.07%	10,285 $130,000
Q2 2018 Aug 14, 2018	SELL	$10.62 - $13.98 $77,154 - $101,564	-7,265 Reduced 30.09%	16,880 $222,000
Q1 2018 May 11, 2018	SELL	$5.9 - $14.99 $56,752 - $144,188	-9,619 Reduced 28.49%	24,145 $328,000
Q4 2017 Feb 13, 2018	BUY	$5.53 - $8.42 $48,802 - $74,306	8,825 Added 35.39%	33,764 $201,000
Q3 2017 Nov 14, 2017	SELL	$6.5 - $10.69 $63,024 - $103,650	-9,696 Reduced 27.99%	24,939 $185,000
Q2 2017 Aug 14, 2017	BUY	N/A	34,635	34,635 $324,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Landscape Capital Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Landscape Capital Management, L.L.C. with notifications on news.